Literature DB >> 28090287

Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).

Soni S Pullamsetti1, Frédéric Perros2, Prakash Chelladurai3, Jason Yuan4, Kurt Stenmark5.   

Abstract

Pulmonary hypertension (PH) is a complex and multifactorial disease involving genetic, epigenetic, and environmental factors. Numerous stimuli and pathological conditions facilitate severe vascular remodeling in PH by activation of a complex cascade of signaling pathways involving vascular cell proliferation, differentiation, and inflammation. Multiple signaling cascades modulate the activity of certain sequence-specific DNA-binding transcription factors (TFs) and coregulators that are critical for the transcriptional regulation of gene expression that facilitates PH-associated vascular cell phenotypes, as demonstrated by several studies summarized in this review. Past studies have largely focused on the role of the genetic component in the development of PH, while the presence of epigenetic alterations such as microRNAs, DNA methylation, histone levels, and histone deacetylases in PH is now also receiving increasing attention. Epigenetic regulation of chromatin structure is also recognized to influence gene expression in development or disease states. Therefore, a complete understanding of the mechanisms involved in altered gene expression in diseased cells is vital for the design of novel therapeutic strategies. Recent technological advances in DNA sequencing will provide a comprehensive improvement in our understanding of mechanisms involved in the development of PH. This review summarizes current concepts in TF and epigenetic control of cell phenotype in pulmonary vascular disease and discusses the current issues and possibilities in employing potential epigenetic or TF-based therapies for achieving complete reversal of PH.

Entities:  

Keywords:  epigenetics; epigenetics/transcription factor–based therapies; histone deacetylases; pulmonary arterial hypertension; transcription factors

Year:  2016        PMID: 28090287      PMCID: PMC5210074          DOI: 10.1086/688908

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  124 in total

1.  Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.

Authors:  Frédéric Perros; Sébastien Bonnet
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

2.  Addressing Complexity in Pulmonary Hypertension: The FoxO1 Case.

Authors:  Roxane Paulin; Evangelos D Michelakis
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

3.  C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs.

Authors:  Madeleine Grooteclaes; Quinn Deveraux; Jeffrey Hildebrand; Qinghong Zhang; Richard H Goodman; Steven M Frisch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-03       Impact factor: 11.205

Review 4.  Chromatin remodeling and transcriptional regulation.

Authors:  R X Luo; D C Dean
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

5.  Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues.

Authors:  T Furuyama; T Nakazawa; I Nakano; N Mori
Journal:  Biochem J       Date:  2000-07-15       Impact factor: 3.857

6.  von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.

Authors:  Michele M Hickey; Jennifer C Lam; Natalie A Bezman; W Kimryn Rathmell; M Celeste Simon
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

7.  FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate.

Authors:  Lin Piao; Vaninder K Sidhu; Yong-Hu Fang; John J Ryan; Kishan S Parikh; Zhigang Hong; Peter T Toth; Erik Morrow; Shelby Kutty; Gary D Lopaschuk; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2012-12-18       Impact factor: 4.599

8.  Regulation of vascularization by hypoxia-inducible factor 1.

Authors:  Gregg L Semenza
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

9.  Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.

Authors:  Lan Zhao; Ali Ashek; Lei Wang; Wei Fang; Swati Dabral; Olivier Dubois; John Cupitt; Soni Savai Pullamsetti; Emanuele Cotroneo; Hazel Jones; Gianpaolo Tomasi; Quang-De Nguyen; Eric O Aboagye; Mona A El-Bahrawy; Gareth Barnes; Luke S Howard; J Simon R Gibbs; Willy Gsell; Jian-Guo He; Martin R Wilkins
Journal:  Circulation       Date:  2013-07-30       Impact factor: 29.690

Review 10.  Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension.

Authors:  Jun-Dae Kim; Aram Lee; Jihea Choi; Youngsook Park; Hyesoo Kang; Woochul Chang; Myeong-Sok Lee; Jongmin Kim
Journal:  Exp Mol Med       Date:  2015-07-31       Impact factor: 8.718

View more
  23 in total

1.  How Many FOXs Are There on The Road to Pulmonary Hypertension?

Authors:  Kurt R Stenmark; Cheng-Jun Hu; Soni S Pullamsetti
Journal:  Am J Respir Crit Care Med       Date:  2018-09-15       Impact factor: 21.405

2.  Network analysis of microRNAs, transcription factors, and target genes involved in axon regeneration.

Authors:  Li-Ning Su; Xiao-Qing Song; Zhan-Xia Xue; Chen-Qing Zheng; Hai-Feng Yin; Hui-Ping Wei
Journal:  J Zhejiang Univ Sci B       Date:  2018 Apr.       Impact factor: 3.066

Review 3.  Epigenetic Inheritance Underlying Pulmonary Arterial Hypertension.

Authors:  Claudio Napoli; Giuditta Benincasa; Joseph Loscalzo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

4.  Endothelial upregulation of mechanosensitive channel Piezo1 in pulmonary hypertension.

Authors:  Ziyi Wang; Jiyuan Chen; Aleksandra Babicheva; Pritesh P Jain; Marisela Rodriguez; Ramon J Ayon; Keeley S Ravellette; Linda Wu; Francesca Balistrieri; Haiyang Tang; Xiaomin Wu; Tengteng Zhao; Stephen M Black; Ankit A Desai; Joe G N Garcia; Xin Sun; John Y-J Shyy; Daniela Valdez-Jasso; Patricia A Thistlethwaite; Ayako Makino; Jian Wang; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2021-10-20       Impact factor: 5.282

5.  MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling.

Authors:  Melina M Musri; Núria Coll-Bonfill; Bradley A Maron; Víctor I Peinado; Rui-Sheng Wang; Jordi Altirriba; Isabel Blanco; William M Oldham; Olga Tura-Ceide; Jessica García-Lucio; Benjamin de la Cruz-Thea; Gunter Meister; Joseph Loscalzo; Joan A Barberà
Journal:  Am J Respir Cell Mol Biol       Date:  2018-10       Impact factor: 6.914

6.  Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension.

Authors:  Hui Zhang; Aya Laux; Kurt R Stenmark; Cheng-Jun Hu
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 7.  Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming.

Authors:  Angelo D'Alessandro; Karim C El Kasmi; Lydie Plecitá-Hlavatá; Petr Ježek; Min Li; Hui Zhang; Sachin A Gupte; Kurt R Stenmark
Journal:  Antioxid Redox Signal       Date:  2017-08-14       Impact factor: 8.401

Review 8.  Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension.

Authors:  Cheng-Jun Hu; Hui Zhang; Aya Laux; Soni S Pullamsetti; Kurt R Stenmark
Journal:  J Physiol       Date:  2018-08-07       Impact factor: 5.182

9.  Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension.

Authors:  Aurélie Hautefort; Julie Chesné; Jens Preussner; Soni S Pullamsetti; Jorg Tost; Mario Looso; Fabrice Antigny; Barbara Girerd; Marianne Riou; Saadia Eddahibi; Jean-François Deleuze; Werner Seeger; Elie Fadel; Gerald Simonneau; David Montani; Marc Humbert; Frédéric Perros
Journal:  Oncotarget       Date:  2017-05-19

Review 10.  Pulmonary Arterial Hypertension: Iron Matters.

Authors:  Latha Ramakrishnan; Sofia L Pedersen; Quezia K Toe; Gregory J Quinlan; Stephen J Wort
Journal:  Front Physiol       Date:  2018-05-31       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.